Rationality of routine clinical use of olokizumab in COVID-19

Rationality of routine clinical use of olokizumab in COVID-19

Routine clinical use of olokizumab in COVID-19 is not recommended. The use of olokizumab is possible in clinical trials.

Bibliographic Details
Main Authors:	V. M. Tsvetov, A. V. Matveev, D. A. Sychev
Format:	Article
Language:	Russian
Published:	Izdatelstvo OKI 2020-10-01
Series:	Качественная клиническая практика
Subjects:	коронавирус олокизумаб covid-19
Online Access:	https://www.clinvest.ru/jour/article/view/530

Similar Items

CHARACTERISTICS OF OLOKIZUMAB PHARMACOKINETICS IN PATIENTS WITH NOVEL CORONAVIRUS INFECTION COVID-19
by: E. V. Tavlueva, et al.
Published: (2022-12-01)

Current and future use of remdesivir in patients with COVID-19
by: V. M. Tsvetov, et al.
Published: (2020-10-01)

Current and future use of dipyridamole in patients with COVID-19
by: I. S. Burashnikova, et al.
Published: (2020-10-01)

Is it possible to use riamilovir to prevent infection and treat COVID-19?
by: V. M. Tsvetov, et al.
Published: (2020-10-01)

Current and future use of umifenovir in patients with COVID-19
by: Yu. Yu. Kiselev, et al.
Published: (2020-10-01)

Possibilities for the use of anakinra in COVID-19
by: V. A. Otdelenov, et al.
Published: (2020-10-01)

Possibilities for the use of tofacitinib in patients with COVID-19
by: A. V. Matveev, et al.
Published: (2020-10-01)

Possibility to use barycytinib in patients with COVID-19, including for treatment of «cytokine storm»
by: V. A. Otdelenov, et al.
Published: (2020-10-01)

Current and future use of colchicine in patients with COVID-19
by: Yu. Yu. Kiselev, et al.
Published: (2020-10-01)

Current and future use of favipiravir in patients with COVID-19
by: A. V. Matveev, et al.
Published: (2020-10-01)

Use of etiotropic and pathogenetic medicines for COVID-19 in patients with renal failure and/or on dialysis
by: V. M. Tsvetov, et al.
Published: (2020-10-01)

Current and future use of vitamin D<sub>3</sub> in patients with COVID-19
by: I. N. Sychev, et al.
Published: (2020-10-01)

Could canakinumab be used for COVID-19?
by: V. A. Otdelenov, et al.
Published: (2020-10-01)

Dexamethasone use in patients with COVID-19
by: V. A. Otdelenov, et al.
Published: (2020-10-01)

Rationale for use mefloquine for COVID-19 treatment
by: V. A. Otdelenov, et al.
Published: (2020-10-01)

Current and future use of aminodihydrophthalazindione sodium in patients with COVID-19, including for «cytokine storm» therapy
by: V. M. Tsvetov, et al.
Published: (2020-10-01)

Change of opinion on the use of hydroxychloroquine for COVID-19 treatment and prevention
by: K. B. Mirzaev, et al.
Published: (2020-10-01)

Methylprednisolone in acute respiratory distress-syndrome in COVID-19: rationales for use, optimal dosage regimens, combined use with tocilizumab
by: K. B. Mirzaev, et al.
Published: (2020-10-01)

Current and future use of angiotensin II receptor blockers in patients with COVID-19
by: A. V. Matveev, et al.
Published: (2020-10-01)

Anticoagulant deprescribing algorithm in patients with COVID-19 after hospital discharge
by: A. V. Krykov, et al.
Published: (2020-10-01)

Possibility to use direct oral anticoagulants to prevent thromboembolic events in patients with COVID-19
by: V. A. Otdelenov, et al.
Published: (2020-10-01)

Possibilities for the use of hydroxychloroquine for pre- and postexposure prophylaxis of SARS-CoV-2 infection among exposed contacts and healthcare personnel
by: V. A. Otdelenov, et al.
Published: (2020-10-01)

Adjusting the role of hydroxychloroquine with or without azithromycin in patients with COVID-19
by: V. A. Otdelenov, et al.
Published: (2020-10-01)

Possibility for the use of bromhexine to prevent infection with SARS-CoV-2
by: K. A. Zagorodnikova, et al.
Published: (2020-10-01)

New Coronavirus Infection (Covid-19): Clinical and Epidemiological Aspects
by: V. V. Nikiforov, et al.
Published: (2020-03-01)

What are the indications for combined use of hydroxychloroquine and lopinavir/ritonavir, and how should treatment safety monitoring be performed?
by: Yu. Yu. Kiselev, et al.
Published: (2020-10-01)

Monitoring of safety using favipiravir: risk management of adverse drug reactions in clinical practice
by: Yu. Yu. Kiselev, et al.
Published: (2020-10-01)

Biochemical, molecular genetic and clinical aspects of COVID-2019
by: E. V. Kashtanova, et al.
Published: (2021-04-01)

Can inhalations of hyaluronidase be used in acute respiratory distress-syndrome in patients with COVID-19?
by: Yu. Yu. Kiselev, et al.
Published: (2020-10-01)

The role of lung ultrasound in the COVID-19
by: D. O. Starostin, et al.
Published: (2020-09-01)

Clinical manifestations and diagnosis of COVID-19 in children
by: A. Ya. Saidova, et al.
Published: (2022-06-01)

Clinical characteristics of a new coronavirus infection (COVID-19) in children hospitalized in a hospital in Karaganda
by: D. G. Bolatova, et al.
Published: (2022-03-01)

The Cases of COVID-19 and Measles Co-Infection in Children
by: N. N. Zvereva, et al.
Published: (2022-01-01)

Severe diseases of the anterior segment of the eye accompanied by somatic pathology and COVID-19: clinical cases under the pandemic
by: O. I. Lebedev, et al.
Published: (2022-06-01)

Features of a new Coronavirus infection in children of different ages
by: M. A. Shakmaeva, et al.
Published: (2021-07-01)

MODERN DIRECTED ANTIVIRAL COVID-19 THERAPY: RESULTS OF MULTICENTER CLINICAL EFFECTIVENESS AND SAFETY STUDY OF FIXED NIRMATRELVIR+RITONAVIR COMBINATION
by: L. A. Balykova, et al.
Published: (2022-10-01)

Vaccines against Covid-19: Comparison, Limitations, the Decrease of Pandemic and the Perspective of Viral Respiratory
by: E. P. Kharchenko
Published: (2021-03-01)

Early Changes in Clinical and Laboratory Parameters in Patients Died of COVID-19
by: K. S. Bakhtiyarova, et al.
Published: (2022-10-01)

Influence of interferon types on COVID-19 prevention and treatment
by: S. S. Saidov, et al.
Published: (2021-10-01)

Management of Neurosurgical Patients During the COVID-19 Pandemic
by: Huaizhang Shi, et al.
Published: (2020-11-01)